Induction of Protective Anti-CTL Epitope Responses against HER-2-Positive Breast Cancer Based on Multivalent T7 Phage Nanoparticles

Pouyanfard, Somayeh; Bamdad, Taravat; Hashemi, Hossein; Bandehpour, Mojgan; Kazemi, Bahram

doi:10.1371/journal.pone.0049539

Cited by 21 publications

(19 citation statements)

References 40 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Healthy mice vaccinated with T7-p66 rejected HER-2 + TUBO cells, with five of the six mice remaining tumor-free 42 days after challenge. Furthermore, therapeutic vaccination with T7-p66 slowed the growth of pre-implanted tumors, eventually resulting in the full regression of HER-2 + tumors 80 .…”

Section: Vnp and Vlp Vaccines And Immunotherapiesmentioning

confidence: 99%

“…Furthermore, therapeutic vaccination with T7-p66 slowed the growth of pre-implanted tumors, eventually resulting in the full regression of HER-2 + tumors. 80 We have recently worked on the development of a HER-2 + breast cancer vaccine using the plant virus PVX. The chemical conjugation of PVX with the P4 B-cell epitope, which contains amino acids 387-394 from the extracellular domain of HER-2, elicited higher titers of HER-2-specific antibodies in mice than soluble P4 alone.…”

Section: Advanced Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Virus‐based nanoparticles as platform technologies for modern vaccines

Lee

Twyman

Fiering

et al. 2016

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Nanoscale engineering is revolutionizing the development of vaccines and immunotherapies. Viruses have played a key role in this field because they can function as prefabricated nanoscaffolds with unique properties that are easy to modify. Viruses are immunogenic through multiple pathways, and antigens displayed naturally or by engineering on the surface can be used to create vaccines against the cognate virus, other pathogens, specific molecules or cellular targets such as tumors. This review focuses on the development of virus-based nanoparticle systems as vaccines indicated for the prevention or treatment of infectious diseases, chronic diseases, cancer, and addiction.

show abstract

Section: Vnp and Vlp Vaccines And Immunotherapiesmentioning

confidence: 99%

Section: Advanced Reviewmentioning

confidence: 99%

Virus‐based nanoparticles as platform technologies for modern vaccines

Lee

Twyman

Fiering

et al. 2016

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Lactate Dehydrogenase (LDH) Assay : LDH assay was used to evaluate the cytotoxicity of cytotoxic T lymphocytes in the combinatorial therapy as previously described . Briefly, B16‐OVA cells were treated with mitomycin C (10 µg mL −1 ) for 2 h and washed with PBS several times to completely remove mitomycin C. Splenocytes from each group ( n = 4) collected at Day 27 were stimulated with the mitomycin C‐treated B16‐OVA cells in RPMI‐1640 with FBS (10%), HEPES (10 × 10 −3 m ), and rIL‐2 (PeproTech) (15 U mL −1 ) for 72 h. After the stimulation, 2 × 10 4 of B16‐OVA cells without any treatment termed as target cells were distributed into triplicate wells of a 96‐well plate in RPMI‐1640 medium (100 µL) supplemented with 2% FBS.…”

Section: Methodsmentioning

confidence: 99%

Bacterium‐Mimicking Vector with Enhanced Adjuvanticity for Cancer Immunotherapy and Minimized Toxicity

Zheng

Chen

et al. 2019

Adv Funct Materials

View full text Add to dashboard Cite

Bacteria are utilized as adjuvants for anticancer immunotherapy. However, immunotherapy with bacteria or their extracts is limited due to their toxicity. On the basis of the innate molecular interactions of foreign molecules from the bacterial components with the host pattern recognition receptors (PRRs), a synthetic adjuvant vector morphologically mimicking the bacterium is engineered, which comprises an optimal combination of components derived from bacterial cell wall, flagellum, and nucleoid. The bacterium-mimicking vectors (BMVs) cooperatively trigger multiple signaling pathways of PRRs and display superior antitumor therapeutic and prophylactic effects to either that of the reported synthetic or bacterium-derived adjuvant. Significantly, BMVs improve the efficacy of photothermal ablation therapy to eradicate 50% of large established tumor in mice that completely reject tumor rechallenge. The synthetic BMVs with the detoxified and controllable composition exhibit minimized toxicity. Such a bacterium-mimicking engineering strategy provides a rational approach to select pathogen-associated molecular patterns, which drives the desired antitumor immune response. The engineered BMVs offer a promising alternative to the bacterial adjuvant for cancer immunotherapy.

show abstract

“…99 There is some evidence to suggest that inclusion of a whole protein tumor antigen in a cancer immunotherapy could actually stimulate tumor cell growth. 99 There is some evidence to suggest that inclusion of a whole protein tumor antigen in a cancer immunotherapy could actually stimulate tumor cell growth.…”

Section: T7 Phagementioning

confidence: 99%

“…Another group targeted the overexpressed HER2 receptor by displaying an immunodominant epitope on T7 phage. 99 There is some evidence to suggest that inclusion of a whole protein tumor antigen in a cancer immunotherapy could actually stimulate tumor cell growth.…”

Section: T7 Phagementioning

confidence: 99%

Phage display as a tool for vaccine and immunotherapy development

Hess

Jewell

2019

Bioengineering & Transla Med

View full text Add to dashboard Cite

Bacteriophages, or phages, are viruses that specifically infect bacteria and coopt the cellular machinery to create more phage proteins, eventually resulting in the release of new phage particles. Phages are heavily utilized in bioengineering for applications ranging from tissue engineering scaffolds to immune signal delivery. Of specific interest to vaccines and immunotherapies, phages have demonstrated an ability to activate both the innate and adaptive immune systems. The genome of these viral particles can be harnessed for DNA vaccination, or the surface proteins can be exploited for antigen display. More specifically, genes that encode an antigen of interest can be spliced into the phage genome, allowing antigenic proteins or peptides to be displayed by fusion to phage capsid proteins. Phages therefore present antigens to immune cells in a highly ordered and repetitive manner. This review discusses the use of phage with adjuvanting activity as antigen delivery vehicles for vaccination against infectious disease and cancer. K E Y W O R D S bacteriophage, biomaterials, drug delivery, immunology, nanotechnology, phage display, vaccine 1 | INTRODUCTION Bacteriophages, or phages, are prokaryotic viruses that specifically infect bacteria, and are the most abundant life form on earth. 1 Phages were first discovered in the early 20th century and noted for their antibacterial activity. The practice of administering phages (i.e., phage therapy) to patients suffering from bacterial infections began shortly after their discovery, but was controversial largely due to lack of mechanistic knowledge and variable success rates. In fact, the treatment was largely abandoned upon the discovery of antibiotics. 2 Research in this field was reenergized, however, following the development of phage display systems in 1985. 3 George Smith, a chemist at the University of Missouri, demonstrated fusion of peptides to the outer (i.e., capsid) proteins of phages enabling surface display. This work, for which Smith shared a Nobel Prize in 2018, laid the ground work for affinity selection, epitope mapping, and antibody discovery. Since this time, phages have been an important tool for the bioengineering field, exploited for a range of applications including theranostics, 4 batteries, 5,6 drug delivery, 7 and vaccine development. 1Phages are one of many nanotechnologies being investigated for these applications. This review will focus on the advantages that phages provide to the nanomedicine field, specifically vaccination and immunotherapy. Nanomedicine ranges from diagnostics to treatments and relies on the fields of biomedical and chemical engineering,

show abstract

Induction of Protective Anti-CTL Epitope Responses against HER-2-Positive Breast Cancer Based on Multivalent T7 Phage Nanoparticles

Cited by 21 publications

References 40 publications

Virus‐based nanoparticles as platform technologies for modern vaccines

Virus‐based nanoparticles as platform technologies for modern vaccines

Bacterium‐Mimicking Vector with Enhanced Adjuvanticity for Cancer Immunotherapy and Minimized Toxicity

Phage display as a tool for vaccine and immunotherapy development

Contact Info

Product

Resources

About